Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BDC-3042

Monoclonal antibody · Agonist of dectin-2 (CLEC6A) · developed by Bolt Biotherapeutics

Phase 1 Most advanced trial (none active)
BOLT Developer
1 Registered trials

What is BDC-3042?

BDC-3042 is an agonistic monoclonal antibody that binds and activates dectin-2 (CLEC6A), an activating C-type lectin receptor expressed by tumor-associated macrophages in the tumor microenvironment. Activation is intended to repolarize these macrophages toward an immunostimulatory state and promote T-cell-mediated anti-tumor immunity. It is being studied in multiple solid tumors, including triple negative breast cancer, renal cell carcinoma, ovarian cancer, head and neck cancer, colorectal cancer, non-small cell lung cancer and melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
dectin-2 (CLEC6A)
Mechanism
Agonist of dectin-2 (CLEC6A)
Pathways
macrophage repolarization, antigen processing and presentation, pro-inflammatory cytokine and chemokine secretion, phagocytosis of tumor cells
Therapy area
Oncology
Developer
Bolt Biotherapeutics, Inc. (BOLT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06052852 Phase 1 Triple Negative Breast Cancer Terminated BOLT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Clear Cell Renal Cell CarcinomaColorectal CancerHead and Neck CancerMelanomaNon-small Cell Lung CancerOvarian CancerTriple Negative Breast Cancer

More from Bolt Biotherapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BOLT page.

Follow BOLT, the company behind BDC-3042

See BOLT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BOLT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.